Primary malignant mucosal melanoma of the upper lip: a case report and review of the literature

BMC Research Notes

Wei Zhang²  Qilin Liu²  Jiping An²  Narayan Sharma Lamichhane¹ 

[1] Department of Oral and Maxillofacial Surgery, School of Stomatology, Jiamusi University, Xuefu Street, Jiamusi 15400, Heilongjiang, China;Department of Oral and Maxillofacial Surgery, Norman Bethune Hospital of Stomatology, Jilin University, Qinghua Road, Changchun 130021, Jilin, People’s Republic of China

关键词: Prognosis;    Oral melanoma;    Malignant melanoma;    Biopsy;   

Others  :  1229934
DOI  :  10.1186/s13104-015-1459-3

 received in 2015-02-20, accepted in 2015-09-18,  发布年份 2015

【 摘 要 】

Background

Malignant melanoma of oral cavity is a rare condition, accounting for 0.5 % of all oral malignancies and about 1–2 % of all melanomas. Oral melanomas have extremely poor prognosis with 5 years survival rate of 12.3 %. The poor prognosis compared to cutaneous melanoma may be attributed to delay in reporting by patient and diagnosis, and apt to become ulcerated due to repeated trauma. The ‘chameleonic’ presentation of a mainly asymptomatic condition, the rarity of these lesions, the poor prognosis and the necessity of a highly specialized treatment are factors that should be seriously considered by the involved health provider.

Case presentation

We present a case of 32 years old male of Han ethnicity with mucosal melanoma of upper lip, comparing his clinical presentation and histological findings at his first visit and following the recurrence. The patient complained of black discoloration on the left side of upper lip since 4 years which gradually increased in size and later involved the skin of the lip. Excision with 5 mm safety margin was performed but the patient presented with the similar lesion after three and half years of the treatment. So, again wide excision with 2 cm safety margin was performed followed by reconstruction of the lip.

Conclusion

This case provides an example of aggressive behavior of mucosal melanoma and emphasizes on the fact that any pigmented lesion detected in the oral cavity may exhibit potential growth and should be submitted to biopsy to exclude malignancy. It also exemplifies of how the time of diagnosis and the evolution of a disease could be seriously influenced by patient’s behavior.

【 授权许可】

   
2015 Sharma Lamichhane et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

【 参考文献 】

• [1]Ullah H, Vahiker S, Singh M, Baig M: Primary malignant mucosal melanoma of oral cavity: a case report. Egypt J Ear Nose Throat Allied Sci 2010, 11:48-50.
• [2]Peacock ME, Stern I, Ditslear CS, Stevens MR, Abdelsayed RA: Melanoma of the maxillary anterior Gingiva. Int J Oral Maxillofac Pathol 2013, 4(4):23-28.
• [3]Garzino-Demo P, Fasolis M, Maggiore GM, Pagano M, Berrone S: Oral mucosal melanoma: a series of case reports. J Craniomaxillofac Surg 2004, 32(4):251-257.
• [4]Manolidis S, Donald PJ: Malignant mucosal melanoma of the head and neck. Cancer 1997, 80(8):1373-1386.
• [5]Chaudhry AP, Hampel A, Gorlin RJ: Primary malignant melanoma of the oral cavity. A review of 105 cases. Cancer 1958, 11(5):923-928.
• [6]Lourenco SV, A MS, Sotto MN, Bologna SB, Giacomo TB, Buim ME, et al.: Primary oral mucosal melanoma: a series of 35 new cases from South America. Am J Dermatopathol 2009, 31(4):323-330.
• [7]Ahmadi-Motamayel F, Falsafi P, Baghaei F: Report of a rare and aggressive case of oral malignant melanoma. Oral Maxillofac Surg 2013, 17(1):47-51.
• [8]Pour MSH: Malignant melanoma of the oral cavity. J Dent Tehran Univ Med Sci 2007, 4:44-51.
• [9]Hajar-Serviansky T, Gutierrez-Mendoza D, Galvan IL, Lammoglia-Ordiales L, Mosqueda-Taylor A, Hernandez-Cázares MdL, et al. A case of oral mucosal melanoma. Clinical and dermoscopic correlation.J Dermatol Case Rep. 2012;6(1):1–4.
• [10]Tanaka N, Amagasa T, Iwaki H, Shioda S, Takeda M, Ohashi K, et al.: Oral malignant melanoma in Japan. Oral Surg Oral Med Oral Pathol 1994, 78(1):81-90.
• [11]Chang AE, Karnell LH, Menck HR: The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Am Coll Surg Comm Cancer Am Cancer Soc Cancer 1998, 83:1664-1678.
• [12]Bansal S, Desai RS, Shirsat P: Amelanotic melanoma of the oral cavity: a case report and review of literature. Int J Oral Maxillofac Pathol 2012, 3(3):31-36.
• [13]Hicks MJ, Flaitz CM: Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol 2000, 36(2):152-169.
• [14]Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V: Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012, 5(8):739-753.
• [15]Bhullar RP, Bhullar A, Vanaki SS, Puranik RS, Sudhakara M, Kamat MS: Primary melanoma of oral mucosa: a case report and review of literature. Dent Res J (Isfahan) 2012, 9(3):353-356.
• [16]Patrick RJ, Fenske NA, Messina JL: Primary mucosal melanoma. J Am Acad Dermatol 2007, 56(5):828-834.
• [17]Sta`rek I, Koranda P, Beneš P: Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma? Melanoma Res 2006, 16(5):423-427.
• [18]Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC cancer staging manual. 7th edition. Springer, New York; 2010.
• [19]Prasad ML, Patel SG, Huvos AG, Shah JP, Busam KJ: Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer 2004, 100(8):1657-1664.
• [20]Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH, et al.: Primary mucosal malignant melanoma of the head and neck. Head Neck 2002, 24(3):247-257.
• [21]Barker BF, Carpenter WM, Daniels TE, Kahn MA, Leider AS, Lozada-Nur F, et al.: Oral mucosal melanomas: the WESTOP Banff workshop proceedings. Western society of teachers of oral pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997, 83(6):672-679.
• [22]Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R: Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 2005, 23(1):16-43.
• [23]Ali S, Ali S: Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 2007, 401(1–2):38-45.
• [24]Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, Louis G, et al.: Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 2003, 278(11):9790-9795.
• [25]Tacastacas JD, Bray J, Cohen YK, Arbesman J, Kim J, Koon HB, et al.: Update on primary mucosal melanoma. J Am Acad Dermatol 2014, 71(2):366-375.
• [26]Buery RR, Siar CH, Katase N, Gunduz M, Lefeuvre M, Fujii M, et al.: NRAS and BRAF mutation frequency in primary oral mucosal melanoma. Oncol Rep 2011, 26(4):783-787.
• [27]Goldinger SM, Murer C, Stieger P, Dummer R: Targeted therapy in melanoma—the role of BRAF, RAS and KIT mutations. Eur J Cancer Suppl 2013, 11(2):92-96.
• [28]Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367(18):1694-1703.
• [29]Wang X, Wu H-M, Ren G-X, Tang J, Guo W: Primary oral mucosal melanoma: advocate a wait-and-see policy in the clinically N0 patient. J Oral Maxillofac Surg 2012, 70(5):1192-1198.
• [30]Chan RC, Chan JY, Wei WI: Mucosal melanoma of the head and neck: 32-year experience in a tertiary referral hospital. Laryngoscope 2012, 122(12):2749-2753.
• [31]Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
• [32]Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26(1):677-704.
• [33]Lian B, Guo J: Checkpoint inhibitors in treatment of metastatic mucosal melanoma. Chin Clin Oncol 2014, 3(3):37.
• [34]Trotti A, Peters LJ: Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol 1993, 9(3):246-250.